Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"RNA, U2 small nuclear 17, pseudogene" (RNU2-17P) is a member of the U2 small nuclear RNA pseudogene family. U2 small nuclear RNAs (snRNAs) are core components of the major spliceosome, where they play essential roles in recognizing branch points and catalyzing pre-mRNA splicing[1]. However, RNU2-17P is annotated as a pseudogene: it is a DNA sequence similar to the functional U2 snRNA genes but is not known to produce a functional RNA product or participate directly in the spliceosome. Pseudogenes such as RNU2-17P typically arise via gene duplication or retrotransposition events and lack functional activity due to mutations, deletions, or lack of regulatory elements required for expression[2]. There is no evidence that this specific pseudogene encodes a protein, has direct biological function, or is considered a drug target; it also does not have established roles in disease, biomarker utility, or safety concerns. The main functional (not pseudogene) U2 snRNAs are important for splicing and RNA processing, but pseudogenes like RNU2-17P are not targets for therapeutic intervention[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 17, pseudogene (RNU2-17P).